Active surveillance in prostate cancer: Role of available biomarkers in daily practice

Abstract

Prostate cancer (PCa) is the most commonly diagnosed cancer in men. The diagnosis is currently based on PSA levels, which are associated with overdiagnosis and overtreatment. More-over, most PCas are localized tumours; hence, many patients with low‐/very low‐risk PCa could benefit from active surveillance (AS) programs instead of more aggressive, active treatments. Het-erogeneity within inclusion criteria and follow‐up strategies are the main controversial issues that AS presently faces. Many biomarkers are currently under investigation in this setting; however, none has yet demonstrated enough diagnostic ability as an independent predictor of pathological or clinical progression. This work aims to review the currently available literature on tissue, blood and urine biomarkers validated in clinical practice for the management of AS patients.